On October 29th, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) will meet to discuss whether several key ingredients, including kisspeptin-10 and l-theanine, should continue to be allowed in traditional compounding. This meeting is pivotal because PCAC’s recommendations often lead to bans on ingredients that have served the health and well-being of millions of Americans. These bans are a serious threat to the practice of compounding pharmacies, which provide customized, natural medicines for patients with specific health needs.

Write to PCAC, the FDA, and Congress, urging them to protect consumer access to these important medicines.